Comparing shorter vs. longer radiation after chemo-immunotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if a shorter course of radiation is as effective as the standard longer course after initial chemotherapy plus immunotherapy in people with advanced esophageal cancer that cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that cannot be surgically removed.
- You are between 18 and 80 years old.
- You have not had any prior chemotherapy, radiation, surgery, targeted therapy, or immunotherapy for your cancer.
- You are able to swallow pills and have adequate organ function (heart, lungs, blood cells, liver, kidneys).
- You can provide a tissue sample from a previous biopsy for analysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This trial tests a shorter course of radiation combined with two drugs (serplulimab and chemotherapy) before surgery for esophageal cancer. It aims to make tumors smaller and improve surgery outcomes.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This study compares two standard approaches for treating esophageal cancer before surgery: chemotherapy combined with radiation versus chemotherapy combined with immunotherapy. The goal is to see which approach works better for shrinking tumors and improving outcomes in patients whose cancer is considered removable.
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.